Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

699
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
699
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

24
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
24
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

561
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
561
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions.

Atherosclerosis plus·2026
Same author

Corrigendum to "Heated tobacco product aerosol emission compared to cigarette smoke: A scoping review" [Toxicol. Rep. 16 (2026) 102209].

Toxicology reports·2026
Same author

Are we underestimating the benefits of lipid-lowering therapies?

Pharmacological reviews·2026
Same author

Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism.

Seminars in thrombosis and hemostasis·2026
Same author

New frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same author

Fragility Analysis of Cardiovascular Outcomes with Finerenone in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

European journal of heart failure·2026
Same journal

Protein acetylation modification in tissue fibrosis: Opportunities and challenges.

Pharmacology & therapeutics·2026
Same journal

Nipocalimab and other FcRn blockers in neuromuscular disorders.

Pharmacology & therapeutics·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
查看所有相关文章

相关实验视频

Updated: Jul 19, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

超越他类药物:降低LDL胆固醇和心血管事件的新药学目标

Emanuel Raschi1, Manuela Casula2, Arrigo F G Cicero3

  • 1Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.

Pharmacology & therapeutics
|August 11, 2023
PubMed
概括
此摘要是机器生成的。

更新的药物提供了创新的方法来降低低密度脂蛋白胆固醇 (LDL-C) 对动脉样硬化心血管疾病 (ASCVD) 的风险. 本综述详细介绍了它们的药理学,益处和风险,以指导临床实践.

关键词:
贝佩多酸是贝佩多酸的一种酸.埃维纳库马布的情况这包括伊朗.这就是LDL胆固醇.洛米塔地区的时间.主要的不良心血管事件.PCSK9 抑制剂的使用.类他类药物是一种药物.

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.4K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

相关实验视频

Last Updated: Jul 19, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.4K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 心血管医学 心血管医学
  • 脂质学 脂质学是指脂质学.

背景情况:

  • 失脂症是动脉样硬化心血管疾病 (ASCVD) 的一个关键可修改的风险因素.
  • 目前的失脂症治疗指南强调基于ASCVD风险的低密度脂蛋白胆固醇 (LDL-C) 降低强度.
  • 关于最佳的脂质标和治疗策略 (逐步与上游治疗) 的争论仍在继续.

研究的目的:

  • 提供基于证据的新型药理学药物治疗失脂血症的综述.
  • 详细介绍新兴的LDL-C降低药物的药理学方面,益处风险概况和以患者为中心的优势.
  • 通过尽量减少治疗惯性来支持临床实践,以控制失脂症.

主要方法:

  • 对最近批准的LDL-C向药物的药理学方面的审查.
  • 对益处风险概况的分析,包括对心血管终点的影响.
  • 评估以患者为中心的优势,例如坚持.

主要成果:

  • 现在有几种针对LDL-C的新型药物类别,包括PCSK9抑制剂,ACL抑制剂,ANGPTL3抑制剂和MTP抑制剂.
  • 这些药物提供了超越他类药物和ezetimibe的创新作用机制.
  • 了解它们的具体特征对于有效的临床应用至关重要.

结论:

  • 新型药理学药物为治疗脱脂症和降低ASCVD风险提供了新的治疗选择.
  • 对这些药物的药理学,疗效,安全性和患者影响的全面了解对于最佳的治疗选择至关重要.
  • 这种知识使临床医生能够量身定制治疗,改善患者的坚持,并最终减少心血管事件.